Health Care • Biotechnology: Pharmaceutical Preparations
$3.22 ▼ -0.28
(-8.13%)
MKT CAP: $54.1M • VOL: 356.4K
52W L $2 52W H $6
ROARABLE / RQD
D • 50/100
PIOTROSKI
5 / 9
HYPD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $813.5K | $57.3K | $3.8K |
| YoY Revenue Growth % | +1318.8% | +1414.0% | — |
| Gross Profit | $510.2K | -$3.9M | — |
| Gross Margin % | 62.7% | -50.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$46.7M | -$48.7M | -$25.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$45.3M | -$49.8M | -$27.3M |
| EBITDA (Normalized) | — | -$48.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$14.8M | -$30.1M | -$23.8M |
| Capital Expenditures (CapEx) | — | $161.5K | — |
| Free Cash Flow (FCF) | -$14.8M | -$30.3M | -$23.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.3M | $2.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $41.1M | -$13.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HYPD.